Russell Frank Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Russell Frank Company’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$977K	Sell	35,150 -25,249	-42%	-$841K	﹤0.01%	2190
2015 Q4	$3.33M	Sell	60,399 -455	-0.7%	-$23K	0.01%	1512
2015 Q3	$2.44M	Sell	60,854 -5,649	-8%	-$184K	﹤0.01%	1728
2015 Q2	$2.13M	Buy	66,503 +26,508	+66%	+$672K	﹤0.01%	1933
2015 Q1	$955K	Buy	+39,995	New	+$896K	﹤0.01%	2165

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Russell Frank Company's ITCI Position: Q1 2016 in Review

Russell Frank Company reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 42% in Q1 2016, selling an estimated $841K and leaving 35,150 shares worth $977K. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

Russell Frank Company first reported a position in ITCI in Q1 2015 and has held it in 5 quarters since. The position peaked at $3.33M in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

Russell Frank Company held 35,150 shares of Intra-Cellular Therapies Inc. worth $977K as of Q1 2016.
Russell Frank Company sold 25,249 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $841K.
Intra-Cellular Therapies Inc. made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2190 holding.
Russell Frank Company first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and has held it in 5 quarters since.
Russell Frank Company's Intra-Cellular Therapies Inc. position peaked at $3.33M in Q4 2015.
127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.